Previous studies have reported substantial involvement of the noradrenergic system in
Parkinson’s disease. Neuromelanin-sensitive MRI sequences and PET tracers have become …

Background Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) cohorts
have provided insights into the earliest neurodegenerative processes in α‐synucleinopathies. …

IMPORTANCE Nonmotor symptoms of Parkinson disease (PD) often predate the movement
disorder by decades. Currently, there is no blood biomarker to define this prodromal phase. …

Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson’s disease
(PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of …

Background: Gait disturbances and balance remain challenging issues in Parkinsonian
patients (PD) with deep brain stimulation (DBS). Short pulse deep brain stimulation (spDBS) …

Patients with Parkinson’s disease (PD) show a broad heterogeneity in clinical presentation,
and subtypes may already arise in prodromal disease stages. Isolated REM sleep behaviour …

Background Skin biopsy is a potential tool for the premortem confirmation of an α‐synucleinopathy.
Objective The aim was to assess the aggregation assay real‐time quaking‐induced …

Background Motor response to dopaminergic therapy is a characteristic of patients with
Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment …

Study Objectives Parkinson’s disease (PD) commonly involves degeneration of sleep-wake
regulating brainstem nuclei; likewise, sleep-wake disturbances are highly prevalent in PD …

Background and Objectives Clinical heterogeneity of patients with Parkinson disease (PD)
is well recognized. PD with REM sleep behavior disorder (RBD) is a more malignant …